| Trial ID: | L1643 |
| Source ID: | NCT02683889
|
| Associated Drug: |
Acthar
|
| Title: |
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
|
| Acronym: |
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
FSGS
|
| Interventions: |
DRUG: Acthar
|
| Outcome Measures: |
Primary: Rate of recurrence of FSGS as seen in renal transplant biopsies proteinuria, This will be studied in the renal transplant biopsies, 2 years|Rate of recurrence of proteinuria, By measurement of urine protein and urine creatinine ratio, 2 years | Secondary: renal function after transplantation, By measurement of the estimated glomerular filtration rate with patient's creatinine, 1 year
|
| Sponsor/Collaborators: |
Sponsor: University of Colorado, Denver
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2019-02-01
|
| Completion Date: |
2024-06
|
| Results First Posted: |
|
| Last Update Posted: |
2024-04-08
|
| Locations: |
Medstar Georgetown Transplant Institute, Washington, District of Columbia, 20005, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02683889
|
